Global Kidney Cancer Drugs Market Trends, Forecast Report 2025-2037
Kidney Cancer Drugs Market size was over USD 6.93 billion in 2024 and is poised to exceed USD 13.9 billion by 2037, witnessing over 5.5% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of kidney cancer drugs is evaluated at USD 7.27 billion.
The primary growth driver of the kidney cancer drugs market is the increasing incidence of kidney cancer worldwide. As the number of diagnosed cases rises, a huge demand for effective treatments fuels demand for new and improved therapies. According to a 2024 report by the National Library of Medicine, kidney cancer (renal cancer) is a disease with an increasing global incidence of 400000 new cases per year and a mortality rate of approximately 175000 deaths per year.
Moreover, kidney cancer drug manufacturers are investing heavily in research and development activities for the production of innovative solutions. Companies investing in R&D are able to develop new drugs and therapies, including targeted treatments, immunotherapies, and combination therapies. These innovations address unmet medical needs and offer improved efficacy, safety, and convenience, expanding the range of available treatment options. For instance, Merck & Co's R&D investment strategy focuses on immuno-oncology, notably the development of its portfolio following the success of its popular cancer treatment, Keytruda (pembrolizumab).
Kidney Cancer Drugs Market: Growth Drivers and Challenges
Growth Drivers
- Advancements in immunotherapy: Advancements in immunotherapy are expanding the range of available treatments, improving patient outcomes, and driving growth in the kidney cancer drugs market. The development of novel checkpoint inhibitors, such as nivolumab (Opdivo) has shown promising results in treating kidney cancer, providing new options for patients and expanding the market. Moreover, combining immunotherapies with other treatment modalities, such as targeted therapies or chemotherapy, is proving to enhance efficacy and improve patient outcomes, driving increased kidney cancer drugs market adoption.
- Aging population: The aging population contributes to a growing patient base since kidney cancer is more common among older adults. Older populations often have more complex health needs and may require more advanced or tailored therapies, which can increase the demand for specialized kidney cancer drugs. According to the National Library of Medicine, kidney cancer incidence rises gradually with age, reaching a peak at around 75 years of age. Approximately 50% of cases are diagnosed before the age of 65 worldwide.
Challenges
- Adverse effects: Severe or unpleasant adverse effects can reduce patient adherence to treatment regimens. This can affect the overall effectiveness of therapies and patient outcomes. Moreover, managing these side effects often requires additional treatments or interventions, which can increase healthcare costs.
- Long regulatory approvals: Prolonged regulatory approval procedures are one of the major challenges impacting drug manufacturers. A delay in the approval process leads to a loss in the current market trend and the availability of innovative therapies. Also, long clinical trials and complex documentation processes limit patients from getting advanced therapeutic approaches.
Kidney Cancer Drugs Market: Key Insights
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
5.5% |
|
Base Year Market Size (2024) |
USD 6.93 billion |
|
Forecast Year Market Size (2037) |
USD 13.9 billion |
|
Regional Scope |
|
Kidney Cancer Drugs Segmentation
Pharmacological Class Type (Angiogenesis Inhibitors, mTOR Inhibitors, Cytokinesis, Others (Immune Checkpoint Inhibitors, CTLA-4 Inhibitors, and Antimetabolites))
Angiogenesis inhibitors segment is anticipated to account for kidney cancer drugs market share of more than 53% by the end of 2037. Angiogenesis inhibitors are divided into two types, one that directly affects microvascular endothelial cells recruited by the tumor, and another that directly targets tumor growth factors. Angiogenesis inhibitors called anti-angiogenic therapy are effective in the treatment of kidney cancer. For instance, angiogenesis inhibitors such as bevacizumab (Avastin) and tyrosine kinase inhibitors (TKIs) which include sunitinib (Sutent) and pazopanib (Votrient), have demonstrated efficacy in treating renal cell carcinoma by blocking the formation of new blood vessels that tumors require to thrive. Angiogenesis inhibitors show positive results when combined with immunotherapy and chemotherapy.
Therapy Type (Targeted Therapy, Immunotherapy, Chemotherapy)
Targeted therapy is estimated to hold a dominant kidney cancer drugs market share throughout the forecast period owing to its effective result in slowing down cancer cell formation. This therapy type is often used to treat rigorous kidney cancer types. According to the Canadian Cancer Society, targeted therapy kills cancerous cells without harming healthy cells. This precision leads to more effective treatments with potentially fewer side effects, making them an ideal option for kidney cancer patients.
The development of new targeted therapies, including tyrosine kinase inhibitors, continues to advance. For instance, Levatinib is an anti-cancer drug used in targeted therapy processes to treat cancer patients including kidney cancer. From the tyrosine kinase inhibitor medication class, levatinib shows effective results in advanced kidney cancer treatment. Pills or tablets are prime forms of medications used in targeted therapy treatment, except temsirolimus as it has an intravenous mode of consumption. These effective characteristics of targeted therapies make them the prime kidney cancer treatment type, leading to high sales of targeted therapy medications.
Our in-depth analysis of the kidney cancer drugs market includes the following segments:
|
Therapy Type |
|
|
Pharmacological Class Type |
|
|
Distribution Channel |
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this ReportKidney Cancer Drugs Industry - Regional Synopsis
North America Market Forecast:
North America industry is set to hold largest revenue share of 35% by 2037, owing to the presence of well-developed healthcare infrastructure. The robust healthcare system facilitates the availability and accessibility of new and innovative kidney cancer drugs. Additionally, the region is a major center for clinical trials and cancer research. This fosters the development of new kidney cancer drugs and drives their availability in the market. The rising prevalence of kidney cancer cases, innovations in cancer drug formulations, and high investments in new product launches by biopharma companies are further fuelling the kidney cancer market growth in North America.
The U.S. kidney cancer drugs market size is poised to witness significant growth till 2037, owing to the rising cases of kidney cancer. According to the American Cancer Society, the U.S. is expected to witness around 81,600 new kidney cancer cases and more than 14,000 deaths by the end of 2024. The majority of people diagnosed with kidney cancer are estimated to be between the age group of 55 and 74. Moreover, comprehensive health insurance coverage and favorable reimbursement policies for cancer treatments facilitate patient access to expensive and innovative therapies, boosting market growth.
Canada is also advancing in the field of cancer treatment due to the presence of several kidney cancer care organizations such as Kidney Cancer Canada, Canadian Cancer Society, and Cancer Care Ontario. Canada represents a substantial market for kidney cancer drugs, with a growing focus on addressing renal cell carcinoma through advanced treatment options. The kidney cancer drugs market growth is driven by increasing incidence rates and the availability of innovative therapies. According to Canadian Cancer Society estimations, around 9,000 individuals in Canada are expected to be detected with kidney and renal pelvis cancer by the end of 2024, out of which 5900 are supposed to be males and 3100 females.
APAC Market Analysis:
The Asia Pacific in kidney cancer drugs market is anticipated to increase at a fast pace through 2037. The rising healthcare expenditures, increasing patient pool in high-potential economies such as China and India, and growing awareness of renal cancer are expected to augment the sales of kidney cancer treatments in the region in the coming years. In India government initiatives on cancer diagnosis and care are set to uplift the profits of kidney cancer drug manufacturers. Indian Cancer Society (ICS) is actively carrying out various cancer awareness programs around the country. According to the Indian Cancer Society (ICS), the cases of cancer are increasing rapidly in India, with kidney cancer constituting 1.3% of the country’s total cancer cases.
According to the World Cancer Research Fund International, China has a high prevalence of kidney cancer across the world. In April 2024, Shanghai Junshi Biosciences Co., Ltd declared that the National Medical Products Administration approved their new drug ‘toripalimab’ for medium to high-risk unresectable or metastatic renal cell carcinoma treatment. Toripalimab in combination with axitinib is approved to be used as the first-line of treatment for renal cancer in China.
Companies Dominating the Kidney Cancer Drugs Landscape:
- AbbVie
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Arlak Biotech
- Apikos Pharma
- Astellas Pharma
- AstraZeneca Plc
- Amgen Inc.
- Biogen Inc.
- Baxter International Inc.
- Byer AG
- GlaxoSmithKline Plc
- JW Therapeutics
- Johnson & Johnson
- Merck & Co., Inc.
- Novo Nordisk A/S
The kidney cancer drugs market is competitive owing to the strong presence of established companies and the emergence of start-ups. The key players are investing heavily in the production of advanced kidney cancer drugs market. This move is set to increase their market reach and earn high profits. Industry giants are also adopting marketing tactics such as collaboration with research institutions to develop innovative kidney cancer drugs and partnerships with other players to boost their regional expansion. New companies are focused on the development of cutting-edge kidney cancer diagnostic and therapeutic solutions to stand out in the crowd.
In the News
- In June 2024, Scientists from the Wistar Institute developed a novel antibody treatment for kidney cancer. The advanced recombinant and synthetic DNA versions of therapeutic antibodies are showing long-lasting and promising results against clear cell renal cell carcinoma (ccRCC).
- In December 2023, The U.S. Food and Drug Administration approved the use of belzutifan for metastatic kidney cancer treatment. Belzutifan developed by the UT Southwestern Researchers was first approved by the FDA in 2021 and in 2023 it received approval for its expanded use.
- In December 2023, Merck received FDA approval for the use of WELIREG, an oral hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor. WELIREG is used for the treatment of advanced renal cell carcinoma (RCC).
- In August 2021, The Japanese Ministry of Health, Labor, and Welfare approved the use of Opdivo (nivolumab) and CABOMETYX (cabozantinib) by Ono and Takeda for metastatic renal cell carcinoma treatment.
Author Credits: Radhika Pawar
- Report ID: 6399
- Published Date: Jan 10, 2025
- Report Format: PDF, PPT
